Research Article
Decreased Expression of CPEB3 Predicts a Poor Prognosis in Patients with Melanoma: A Study Based on TCGA Data
Table 2
Logistic regression analysis of CPEB3 expression associated with clinical pathological characteristics.
| Characteristics | Total () | Odds ratio in CPEB3 expression | value |
| New event type (metastasis vs. recurrence) | 173 | 0.51 (0.26-0.98) | 0.045 | T stage (T0-2 vs. T3-4) | 384 | 0.56 (0.37-0.85) | 0.006 | N stage (N0 vs. N1-3) | 411 | 0.96 (0.65-1.42) | 0.843 | M stage (M0 vs. M1) | 440 | 1.04 (0.45-2.39) | 0.927 | Clinical stage (stages 0-II vs. stages III-IV) | 416 | 0.99 (0.68-1.46) | 0.972 | Melanoma Clark level (I-III vs. IV-V) | 319 | 0.54 (0.33-0.87) | 0.012 | Tumor status (tumor free vs. with tumor) | 460 | 0.84 (0.58-1.21) | 0.35 | Tumor tissue site (extremities vs. trunk) | 366 | 0.73 (0.48-1.10) | 0.134 | Melanoma ulceration (no vs. yes) | 311 | 0.61 (0.39-0.95) | 0.029 |
|
|